Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
about
Immunobiology and immunotherapy in genitourinary malignanciesThe role of mycobacterial cell wall nucleic acid complex in the treatment of bacillus Calmette-Guérin failures for non-muscle-invasive bladder cancerBacille-Calmette-Guerin non-responders: how to manageTreatment of non-muscle invasive bladder cancer with Bacillus Calmette-Guerin (BCG): Biological markers and simulation studiesManagement of carcinoma in situ of the bladder: best practice and recent developmentsIntravesical immunotherapy in nonmuscle invasive bladder cancerIntravesical chemotherapy in non-muscle-invasive bladder cancerLow-Dose Versus Standard Dose of Bacillus Calmette-Guerin in the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-AnalysisMolecular cancer prevention: Current status and future directionsApplications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapyBacillus Calmette-Guérin (BCG) Treatment Failures in Non-Muscle Invasive Bladder Cancer: What Truly Constitutes Unresponsive DiseaseHow to optimally manage elderly bladder cancer patients?Bladder cancer: narrowing the gap between evidence and practiceCurrent clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS).Optimal management of high-risk T1G3 bladder cancer: a decision analysisAntimicrobial peptides of the Cecropin-family show potent antitumor activity against bladder cancer cellsUpdate on the management of non-muscle invasive bladder cancer.A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer.Prognostic value of impaired estimated glomerular filtration rate in intravesical BCG-treated non-muscle-invasive bladder cancer patientsIntravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion.Percutaneous nephroscopic surgery.Canadian guidelines for treatment of non-muscle invasive bladder cancer: a focus on intravesical therapy.Patterns of care for early stage bladder cancer.Advances in intravesical therapy for the treatment of non-muscle invasive bladder cancer (Review).Multi-institutional analysis of sequential intravesical gemcitabine and mitomycin C chemotherapy for non-muscle invasive bladder cancer.Could hyaluronic acid (HA) reduce Bacillus Calmette-Guérin (BCG) local side effects? Results of a pilot study.Randomized controlled trial of oxybutynin extended release versus placebo for urinary symptoms during intravesical Bacillus Calmette-Guérin treatment.Biopsies of the normal-appearing urothelium in primary bladder cancer.Genetic variations in the sonic hedgehog pathway affect clinical outcomes in non-muscle-invasive bladder cancerTumour seeding as a result of intraperitoneal perforation during transurethral resection of non-muscle invasive bladder cancerAssociation of polymorphisms in oxidative stress genes with clinical outcomes for bladder cancer treated with Bacillus Calmette-Guérin.Origin of multifocal carcinomas of the bladder and upper urinary tract: molecular analysis and clinical implications.Immunotherapy for bladder cancer.Update on intravesical agents for non-muscle-invasive bladder cancerBCG-mediated bladder cancer immunotherapy: identifying determinants of treatment response using a calibrated mathematical model.Intravesical therapy for urothelial carcinoma of the urinary bladder: a critical review.Use of bacille Calmette-Guérin in superficial bladder cancer.Optimal schedule of bacillus calmette-guerin for non-muscle-invasive bladder cancer: a meta-analysis of comparative studiesSequential intravesical mitomycin plus Bacillus Calmette-Guérin for non-muscle-invasive urothelial bladder carcinoma: translational and phase I clinical trialProactive approach to treat high-grade lamina-invasive bladder cancer.
P2860
Q26738668-4E41C611-2DC2-4E5F-8F12-DF95F65310C5Q26770422-54221382-9AB6-4720-A814-35086A4059F2Q26773679-2D89ACCE-63DB-42BD-A3ED-A0F66244ED33Q26775541-34D1DD42-CA36-4C02-A7D1-02EE81B39D54Q26775772-9B6A98A6-C4CA-4F7E-8835-D599642DBA36Q26775979-FABE1BCB-C669-4427-8D4E-D995F738B0A0Q26775982-9A75ABB6-329A-475D-878B-49801C64956DQ26776501-3AF57EF1-0F91-42A1-8A89-57C9A315722AQ26797207-C2D5A177-3AAE-4C6B-B846-EBC7697D2491Q26798372-570DE9DA-C2AD-436B-9C88-4C97A9690533Q27011829-EA877417-DDE6-485E-9CDF-8A182979E457Q28076939-6F541960-2D5B-49BD-BE1A-014778E8302DQ30362052-BA7B4F19-4171-4ACF-8F43-4CF4FA25244AQ30596342-32766492-3B7A-4A36-A33E-9BF890978324Q33300413-E37BF98A-9F6C-4B8D-AB63-A91400E86858Q33322232-272EF54F-A061-4641-AB07-83ED84714AA9Q33613070-C6FE566A-DF87-4357-A45C-09D2C49E1B8CQ33640357-31AE3F5B-CE38-44BA-A545-73C3FDD9AFE2Q33684090-D8DAE048-3A47-426B-A348-6E6E58520652Q33711371-F6EF36BA-2C3D-4486-9BA0-1F7AB1A50CC4Q33866186-F6916467-7971-40B2-BE96-08D897C4E689Q33869233-44DD12FE-C4B3-46DB-8E50-83C74A63691FQ33875940-AF794EF0-2038-40F0-8A83-ADAC07F29C86Q33933049-EDE78506-F540-4030-819B-332B4627D784Q33959824-38F3F9AF-437B-4006-9F72-F1C0AA7A5B1EQ34063277-6AB56584-E3F8-4235-A844-A484BC8A0E68Q34115106-EA3F3806-A186-42F9-98AD-4BBA2E09772FQ34146737-3F841FD3-31FD-4027-B818-E2EAEB293518Q34203675-376A0A42-4A89-4F28-87ED-E3B5BB39E3F1Q34236110-836A39A9-B4E6-4F95-B11E-4D1C128C0D12Q34305503-59844718-BC41-4002-B15A-EBF86FB69E8DQ34452391-B026499B-2FF0-421B-99BF-DAC70A1519A0Q34477444-7352AE30-2956-4EC5-9770-66411591269FQ34584575-C3133142-06C9-43F0-A6BD-272BDB93A975Q34602312-C88403F1-54A6-48FA-AA2E-AF5D08A7388FQ34751946-91AC6807-64E1-4330-B261-42B04BECEACAQ34788204-8C5449C3-49D5-42B9-996E-F98CF30A1F4DQ34799858-CB3F594E-7FDA-45D6-AD7A-B43FD6653951Q34979760-4F059031-FC09-46E9-880E-28B42EC2EE70Q35125741-83C62994-861F-4116-B1E9-264641ACCF47
P2860
Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Maintenance bacillus Calmette- ...... outhwest Oncology Group Study.
@en
Maintenance bacillus Calmette- ...... outhwest Oncology Group Study.
@nl
type
label
Maintenance bacillus Calmette- ...... outhwest Oncology Group Study.
@en
Maintenance bacillus Calmette- ...... outhwest Oncology Group Study.
@nl
prefLabel
Maintenance bacillus Calmette- ...... outhwest Oncology Group Study.
@en
Maintenance bacillus Calmette- ...... outhwest Oncology Group Study.
@nl
P2093
P1476
Maintenance bacillus Calmette- ...... outhwest Oncology Group Study.
@en
P2093
Blumenstein BA
Crawford ED
Crissman JD
Gottesman JE
Grossman HB
Leimert JT
P304
P356
10.1097/00005392-200004000-00014
P407
P577
2000-04-01T00:00:00Z